Strong SA, Peto T, Bunce C, et al. - In this first prospective exploratory study comprising 30 patients (30 eyes), researchers tested the effectiveness and safety of intravitreal aflibercept (Eylea) (ivA) for retinitis pigmentosa-associated cystoid macular oedema (RP-CMO) at 12 months via mean central macular thickness (CMT) and reported adverse events. Serial ivA was administered by loading dose (three injections) followed by a treat and extend protocol over 12 months. Twenty-nine out of 30 individuals followed up for 12 months. This investigation shows the safety as well as the acceptability of serial ivA in patients with RP-CMO, effective at decreasing CMT in 37.9% of patients. After their first injection, all patients who showed anatomical response did so. The longer duration of CMO did not adversely affect the anti-VEGF response. More analysis of the efficacy of VEGF blockade in RP-CMO in a larger cohort of patients with shorter CMO duration would be beneficial to better define.